Short answer
Niagen Bioscience, Inc. (NAGE) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $27M (down 20.0% year over year) with net income of −$1M.
Q3 2026 key financials · XBRL
- Revenue
- $27M
- −20.0% YoY · −8.7% QoQ
- Net income
- −$1M
- −125.6% YoY · −221.8% QoQ
- Operating margin
- -5.8%
- Gross margin
- 62.9%
- EPS (diluted)
- −$0.02
- −140.0% YoY · −200.0% QoQ
Source: XBRL data from the Niagen Bioscience, Inc. (NAGE) Q3 2026 10-Q on SEC EDGAR. USD.
Niagen Bioscience, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $27.2M, down 20% YoY from $34.0M, driven by Consumer Products and Ingredients declines
- Ingredients worst segment: sales $3.8M, down 47%; Consumer Products best: sales $23.3M, down 10%
- Gross margin 62.9% vs 64.5% YoY, with Ingredients margin 51.3% vs 59.1%
- Cash $69.5M at September 30; operating cash flow $4.2M vs $12.8M YoY
- $5.1M investing inflow from divestiture; $4.6M financing outflow including $5.1M share repurchases
- Near-term headwinds: softer downstream demand, variable partner orders, competitive pricing, and elevated marketing investment
Risk Factors
- Competitive risk: FDA’s September 2025 NMN decision increased lower-priced competition, with ingredient-business financial impacts already experienced
- Legal risk: Elysium fee award of approximately $9.2 million reversed October 30, 2026, but further review remains possible
- Regulatory risk: Putative consumer class actions challenge Tru Niagen® advertising and marketing claims
- Operational risk: Marketplace suspension of a Tru Niagen® listing during Q2 2026 caused lost revenue
- Liquidity risk: $69.5 million cash and no line-of-credit borrowings outstanding, with additional financing potentially required beyond twelve months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Niagen Bioscience, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.